Search results
Results from the WOW.Com Content Network
The main difference is in the reversal of these two types of neuromuscular-blocking drugs. Non-depolarizing blockers are reversed by acetylcholinesterase inhibitor drugs since non-depolarizing blockers are competitive antagonists at the ACh receptor so can be reversed by increases in ACh. The depolarizing blockers already have ACh-like actions ...
Depolarizing neuromuscular blockers: Depolarizing agents act as agonists for acetylcholine receptors. Succinylcholine is currently the only depolarizing neuromuscular blocking drug that has been placed in ongoing clinical use. Its pharmacological structure resembles two acetylcholine molecules combined through acetate methyl groups. [11]
A muscle relaxant is a drug that affects skeletal muscle function and decreases the muscle tone. It may be used to alleviate symptoms such as muscle spasms, pain, and hyperreflexia. The term "muscle relaxant" is used to refer to two major therapeutic groups: neuromuscular blockers and spasmolytics.
Bupropion – Ganglion blocker [25] [26] [27] Dextromethorphan - Cough suppressant and ganglion blocker [28] [29] [30] Doxacurium – Nondepolarizing skeletal muscular relaxant; Hexamethonium – Ganglion blocker; Mecamylamine – Ganglion blocker and occasional smoking cessation aid [31] Tubocurarine - Nondepolarizing skeletal muscular relaxant
Pancuronium is a typical non-depolarizing curare-mimetic muscle relaxant. It competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction by blocking the binding of acetylcholine. It has slight vagolytic activity, causing an increase in heart rate, but no ganglioplegic (i.e., blocking ganglions) activity.
A nicotinic antagonist is a type of anticholinergic drug that inhibits the action of acetylcholine (ACh) at nicotinic acetylcholine receptors.These compounds are mainly used for peripheral muscle paralysis in surgery, the classical agent of this type being tubocurarine, [1] but some centrally acting compounds such as bupropion, mecamylamine, and 18-methoxycoronaridine block nicotinic ...
Rocuronium bromide is a competitive antagonist for the nicotinic acetylcholine receptors at the neuromuscular junction. Of the neuromuscular-blocking drugs it is considered to be a non-depolarizing neuromuscular junction blocker, because it acts by dampening the receptor action causing muscle relaxation, instead of continual depolarisation which is the mechanism of action of the depolarizing ...
Phase 1 block does not show fade under tetanic stimulation. With further administration of depolarizing neuromuscular blocking agent, an effect that is similar to the response of muscle to non-depolarizing neuromuscular blocking agents can be observed. This response, termed phase 2 block, will demonstrate similar fade under tetanic stimulation ...